Long-term outcome comparison for standard fractionation (≥59 Gy) versus hyperfractionated (≥45 Gy) radiotherapy plus concurrent C chemotherapy for limited-stage small-cell lung cancer

Background: Concurrent chemoradiotherapy (CCRT) is commonly employed in limited-stage small-cell lung cancer (LS-SCLC); however, the optimal radiotherapy regimen is still unknown. This 3-institution analysis compares long-term disease control and survival outcomes for once- (QD) versus twice-daily (BID) radiotherapy at contemporary doses. Methods and Materials: Data were collected for LS-SCLC patients treated with platinum-based CCRT and planned RT doses of >= 5940 cGy at >= 180 cGy QD or >= 4500 cGy at 150 cGy BID. Comparative outcome analyses were performed for treatment groups. Results: From 2005 through 2014, 132 patients met inclusion criteria for analysis (80 QD, 52 BID). Treatment groups were well-balanced, excepting higher rate of advanced mediastinal staging, longer interval from biopsy to treatment initiation, and lower rate of prophylactic cranial irradiation for the QD group, as well as institutional practice variation. At median survivor follow-up of 33.5 months (range, 4.6-105.8), 80 patients experienced disease failure (44 QD, 36 BID), and 106 died (62 QD, 44 BID). No differences in disease control or survival were demonstrated between treatment groups. Conclusion: The present analysis did not detect a difference in disease control or survival outcomes for contemporary dose QD versus BID CCRT in LS-SCLC. (C) 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.